Healthcare procurement has moved from a back-office purchasing function to a strategic lever for access, system resilience, and cost optimisation. This shift is most urgent in Africa, where procurement weaknesses directly affect medicine availability, product quality, and out-of-pocket spending, and increasingly relevant in the GCC, where health systems are moving from volume-led procurement toward value-based purchasing, localisation, and supply security.

Why healthcare procurement matters now

Healthcare procurement is no longer about obtaining the lowest price; it now determines whether health systems can secure essential medicines, vaccines, diagnostics, medical devices, and consumables at the right quality, price, and time. Procurement failures translate directly into patient harm, through stock-outs, substandard products, or unaffordable medicines.

In Africa, healthcare procurement is evolving amid ongoing efforts to strengthen supply resilience, forecasting capabilities, regulatory systems, and access to essential healthcare products. Import dependence and fragmented purchasing structures continue to shape procurement priorities across many markets. The continent's health systems often operate in reactive mode, purchasing in emergencies, at higher unit prices, with limited visibility into facility-level inventory.

Related:Designing Healthcare for the Future: Innovation, Access, and Equity at Scale

In the GCC, the agenda is increasingly linked to healthcare transformation, cost optimisation, localisation, value-based care, and strategic supply security. Countries such as Saudi Arabia and the UAE are not primarily constrained by availability; instead, they are working to optimise health expenditure, link purchasing to outcomes, and reduce reliance on branded imports.

In both contexts, the strategic imperative is the same: move procurement from a transactional, price-focused function to a value-driven, intelligence-led capability that supports health system resilience.

Two regions, different starting points, converging procurement priorities

Despite distinct maturity levels and system architectures, Africa and the GCC face a shared strategic imperative: to shift procurement from a price-led, reactive function toward a resilient, value-based, and intelligence-driven capability.

The challenge: Africa's procurement imperative

The GCC agenda: From price-led to value-based procurement

The GCC-Africa procurement partnership opportunity

Local and regional manufacturing should be treated as a procurement policy tool, not only an industrial policy ambition. GCC capital, logistics platforms, regulatory maturity, and purchasing scale can be linked with African demand, regional manufacturing sites, and enabled market access. The opportunity is not to localise everything, but to prioritise essential medicines, vaccines, diagnostics, sterile injectables, insulin, PPE, and high-burden disease products.

Related:From Health Policy to Real-World Impact

GCC capabilities

Partnership mechanisms

African market needs

Shared outcome: Building a more integrated and resilient health supply architecture

A stronger GCC-Africa procurement partnership could create benefits that extend beyond individual transactions or manufacturing investments. By connecting GCC capital, purchasing power, logistics capabilities, and regulatory experience with Africa's growing healthcare demand, manufacturing potential, and regional market integration, both regions can build a more coordinated health supply architecture.

Related:Positioning Africa’s health sector for long-term competitiveness and growth

For African health systems, this could improve the availability and affordability of priority medicines, vaccines, diagnostics, and medical supplies while reducing exposure to global supply disruptions and emergency purchasing. Longer-term procurement agreements and aggregated demand could provide manufacturers with greater volume certainty, supporting sustainable local and regional production. For GCC countries, the partnership could diversify supplier networks, reduce overdependence on a limited number of international production hubs, and create access to new healthcare investment and manufacturing opportunities. African manufacturing platforms could also become part of GCC strategic sourcing and stockpile strategies, particularly for essential and high-demand products.

The shared outcome would therefore be greater regional health security, improved purchasing efficiency, stronger supply continuity, and reduced procurement risk. Rather than operating only as investors and buyers, GCC and African stakeholders could become long-term partners in developing manufacturing capacity, quality systems, resilient supply chains, and more predictable healthcare markets.

Conclusion

Healthcare procurement is becoming one of the most important strategic capabilities within modern health systems. In Africa, the immediate priority is to strengthen access, affordability, quality assurance, demand visibility, and supply continuity while in the GCC, the focus is shifting toward value-based purchasing, cost optimisation, localisation, supplier diversification, and strategic supply security.

Although the two regions begin from different positions, their procurement priorities are increasingly converging. Both require stronger demand forecasting, better use of procurement data, improved supplier performance management, greater coordination between regulators and purchasers, and procurement models that reward long-term value rather than the lowest initial price. The next phase of procurement transformation should therefore focus on building intelligence-led and outcome-oriented systems. This includes pooled and centralised purchasing where appropriate, digital procurement control towers, risk-based supplier management, stronger quality assurance, and carefully targeted local and regional manufacturing.

By aligning investment, procurement commitments, manufacturing development, technology transfer, and regulatory cooperation, both regions can create a more resilient and mutually beneficial healthcare supply system. The ultimate objective is not simply to purchase products more efficiently, but to ensure that the right healthcare products consistently reach the right patients, at the required quality, at an affordable cost, and without disruption.